Inhibitors targeting TGF-β and Smad2/3 signaling can stimulate CEC differentiation and promote their maturation, thereby neutralizing their suppressive effects (202, 246), and have been proven effective in mouse models of cancer. The gene discussed is TGFB1; the disease is cancer.